Precigen reports second quarter and first half 2024 financial results and business updates

– in june 2024, the company announced groundbreaking pivotal study data for prgn-2012 gene therapy at the 2024 asco annual meeting in which more than half of rrp patients achieved complete response – – in july 2024, the company appointed phil tennant as chief commercial officer to spearhead potential prgn-2012 commercial launch – – in august 2024, the company announced a strategic reprioritization of its pipeline to focus on advancement of its lead program, prgn-2012 in rrp – – prgn-2012 rolling bla submission, under an accelerated approval pathway, is anticipated in the second half of 2024; the company has initiated enrollment in the confirmatory clinical trial of prgn-2012 – – in august 2024, the company strengthened its cash position by raising approximately $31.4 million via a public offering of common stoc k – germantown, md. , aug. 14, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2024 financial results and business updates.
PGEN Ratings Summary
PGEN Quant Ranking